2 hours Zevra Therapeutics (NASDAQ:ZVRA) Receives “Buy” Rating from HC Wainwright MarketBeat
HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday.
HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday.